● LIVEInternational Clinical Excellence Award for Delta G Avaris' Dr. Evgenii Rubalskii/Research grant for the advancement of our phage therapy/GMP-certified drug production in preparation/WHO classifies AMR as a global health threat/Research and development in bacteriophage biology/● LIVEInternational Clinical Excellence Award for Delta G Avaris' Dr. Evgenii Rubalskii/Research grant for the advancement of our phage therapy/GMP-certified drug production in preparation/WHO classifies AMR as a global health threat/Research and development in bacteriophage biology/
    Delta G Avaris

    News

    We offer a complete package — also for the media.

    Good news and important updates – stay informed in our News section

    Fachforum zur Stärkung der Resilienz des Gesundheitswesens im Deutschen BundestagForum

    Delta G Avaris Attends Forum on Strengthening Healthcare Resilience at the German Bundestag

    Delta G Avaris attended the Forum on Industrial Healthcare, hosted by the SPD parliamentary group at the German Bundestag—joining policymakers, healthcare leaders, industry, scientists, and the Bundeswehr to discuss how Germany can strengthen the resilience of its healthcare system.

    July 2026

    Das Team von Delta G Avaris auf der Viruses of Microbes 2026Conference

    Delta G Avaris Joins the Global Phage Community at Viruses of Microbes 2026

    Delta G Avaris participated as a Silver Sponsor at Viruses of Microbes 2026 in Prague—one of the world's leading bacteriophage conferences—hosting an exhibition booth and connecting with the global phage community.

    July 2026

    Dr. Evgenii Rubalskii – Personalized Phage Therapy Clinical Excellence Award, ValenciaAward

    International Clinical Excellence Award goes to Delta G Avaris' Dr. Evgenii Rubalskii

    Dr. Evgenii Rubalskii, Head of Research & Development, was honored with the Personalized Phage Therapy Clinical Excellence Award at the Targeting Phage Therapy 2026 Conference in Valencia, Spain.

    June 2026

    Global Solutions Summit 2026 – BerlinConference

    Delta G Avaris at the Global Solutions Summit 2026: Advancing Dialogue on Global Health, Prevention, and Innovation

    Delta G Avaris was proud to participate in the Global Solutions Summit 2026, held in Berlin, Germany.

    June 2026

    Bakteriophagen-Plaques – GMP-ProduktionCompany News

    Delta G Avaris acquires GMP production site of Richter Biologics in Hannover for phage manufacturing

    Effective May 1, 2026, Delta G Avaris has acquired the GMP production site of Richter Biologics in Hannover, expanding its bacteriophage manufacturing capabilities.

    05/01/2026

    ESCMID Global 2026Conference

    Participation at ESCMID Global 2026: Advances in Phage Therapy from Hannover

    Hannover Medical School presented current results on the clinical application of bacteriophages at the ESCMID Global Congress in Munich.

    04/22/2026

    BSFZ-Siegel 2026 – ForschungszulageResearch & Development

    Delta G Avaris receives approximately €900,000 in research funding for the further development of phage therapy

    Funding of approximately €900,000 for research and development activities in the field of phage therapy.

    04/07/2026

    WISO – ZDF WirtschaftsmagazinMedia Coverage

    WISO report by ZDF

    Be inspired by the fascinating capabilities of phage therapy - in the interview from minute 16:22 to 22:02.

    Read More

    10/27/2025

    Contact

    Press Contact

    For press inquiries and media inquiries, please contact our communications department.

    BSFZ-Siegel 2026 – Forschungszulage

    Some images on this website were created with the assistance of artificial intelligence. Learn more

    © 2026 Delta G Avaris GmbH. All rights reserved. · Germany

    We use cookies to provide you with the best possible experience on our website. Learn more